Clinical trials: Cirrhosis Liver
Portal Hypertension Related to Cirrhosis, Ascites
Development and Validation of a TIPS Prognostic Model
This multicenter, prospective observational study aims to learn whether a prediction model using routine clinical data, imaging findings (including spleen stiffness measurement), and circulating biomarkers can predict stent…
- Conditions
- Portal Hypertension Related to Cirrhosis, Ascites, Esophageal Variceal Bleeding
- Trial name
- C-SIPS (NCT07909850)
- Volunteers
- 1,490 people
- Sponsor
- The Second Affiliated Hospital of Chongqing Medical University
MASLD, Fibrosis of Liver
Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI
The goal of this clinical trial is to learn whether an artificial intelligence (AI) tool called FibroX can help primary care providers better diagnose significant liver fibrosis (≥F2) and clinically significant portal…
- Trial name
- NCT07305324
- Testing
- FibroX, Usual Care
- Volunteers
- 40 people
- Sponsor
- Yale University
Systemic Inflammatory Markers, Portal Vein Thrombosis
A Practical Nomogram Based on Systemic Inflammatory Markers for Predicting Portal Vein Thrombosis in Patients With Liver Cirrhosis
Immunothrombosis has recently been used to describe the responses/mechanisms in thrombosis. Systemic inflammatory markers are prognostic markers for a variety of thrombotic conditions; however, their potential value in predicting…
- Trial name
- NCT05541562
- Testing
- clinical laboratory tests, and imaging characteristics
- Where
- China
- Volunteers
- 478 people
- Sponsor
- The Affiliated Hospital of Qingdao University
Chronic Hepatitis C Virus (HCV) Infection Genotype 1
A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection
The purpose of this study was to evaluate the effect of treatment with ABT-450 co-formulated with ritonavir and ABT-267 (ABT-450/r/ABT-267) and ABT-333; 3-DAA regimen, with or without ribavirin (RBV) in adults with chronic…
- Trial name
- TOPAZ-I (NCT02219490)
- Testing
- ABT-450/r/ABT-267, ABT-333, Ribavirin (RBV)
- Where
- 187 sites in Algeria, Australia and 25 more
- Volunteers
- 1,596 people
- Sponsor
- AbbVie
Decompensated Cirrhosis
Hospital @ Home Model of Care for Cirrhosis
The purpose of this study is to work with patients diagnosed with end-stage liver disease to understand their perspectives on the Health at Home (H@H) Program, including desired outcomes and expectations, perceived barriers, and…
- Trial name
- H@H (NCT06396897)
- Testing
- Indiana University Health Hospital at Home Program
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Indiana University
Cirrhosis, Liver Disease Chronic
Inferior Vena Cava Pressure as Alternative to Hepatic Venous Pressure for EUS-guided Portal Pressure Gradient Measurement
This study investigates a new, simplified approach to measuring blood pressure within the liver (portal hypertension) using Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement (EUS-PPG).
- Conditions
- Cirrhosis, Liver Disease Chronic, Portal Hypertension
- Trial name
- EUS-VEIN (NCT07703540)
- Testing
- HVP-PPG and IVCP-PPG
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- University Hospital Muenster
Diabetes
Screening for Liver Fibrosis by Using Non-invasive Methods in Patients With Diabetes. A Prospective Study
The aim of this study is to evaluate liver fibrosis using FibroScan and biochemical markers in patients with diabetes.
- Trial name
- DIABSCAN (NCT01306110)
- Where
- France
- Volunteers
- 277 people
- Sponsor
- Association HGE CHU Bordeaux Sud
Primary Biliary Cholangitis (PBC)
CS0159 in Chinese Patients With PBC (Primary Biliary Cholangitis)
A phase II study to evaluate safety, tolerability and efficacy of CS0159 in patients with PBC (Primary Biliary Cholangitis).
- Trial name
- NCT05896124
- Testing
- 2mg CS0159
- Where
- 16 sites in China
- Volunteers
- 75 people
- Sponsor
- Cascade Pharmaceuticals, Inc
Alcoholic Liver Disease
Influence of Adiponutrin in Chronic Liver Disease
Increasing evidence attests the influence of multiple metabolic genetic risk factors in the progression of alcoholic liver disease.
- Trial name
- NCT01122797
- Where
- Belgium
- Volunteers
- 658 people, healthy volunteers welcome
- Sponsor
- Erasme University Hospital
Hepatic Cirrhosis, Ascites
Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis
For hepatic cirrhosis subjects with ascites or lower extremities, to study Pharmacokinetics, pharmacology, and safety of the drug under fasting condition.
- Trial name
- NCT01359462
- Testing
- tolvaptan
- Where
- China
- Volunteers
- 11 people
- Sponsor
- Otsuka Beijing Research Institute
Fibrosis, Hepatitis C Chronic
Pirfenidone, an Antifibrotic and Antiinflammatory Drug
The aim of this study was to assess whether two-year treatment with Pirfenidone influence necro-inflammation, fibrosis and steatosis in patients with chronic hepatitis C.
- Trial name
- NCT02161952
- Testing
- Pirfenidone
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Guadalajara
Upper Digestive Bleeding, Cirrhosis
Efficacity and Safety of Tranexamic Acid in Cirrhotic Patients Presenting With Acute Upper Gastrointestinal Bleeding
Upper digestive bleeding. Upper gastrointestinal haemorrhage is a common cause of decompensated cirrhosis and is associated with a high mortality rate among cirrhotic patients.
- Trial name
- EXARHOSE (NCT03023189)
- Testing
- Tranexamic acid
- Where
- 3 sites in France
- Volunteers
- 500 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Septic Shock, Cirrhosis
Cirrhotic Patients With Septic Shock
Cirrhotic patients have a poor outcome in intensive care unit (ICU). Septic shock is a leading cause of ICU admission and death in this specific population.
- Trial name
- NCT03987048
- Testing
- Measure of short- and long-term mortality and analysis of independent predictors of short- and long-term mortality.
- Where
- France
- Volunteers
- 149 people
- Sponsor
- Hospices Civils de Lyon
Hepatitis B Virus Related Cirrhosis
Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV
Liver Cirrhosis is a common pathological consequence of chronic liver disease. Hepatitis B Virus (HBV) is one of most etiologies of Liver cirrhosis in China.
- Trial name
- NCT02241616
- Testing
- Entecavir+Fuzheng Huayu+TCM Granule
- Where
- 20 sites in China
- Volunteers
- 350 people
- Sponsor
- ShuGuang Hospital
Iron Deficiency Anemia, Chronic Liver Failure
Lactoferrin in Treatment of Fe Deficient Anemia In Cirrhosis
Iron deficiency and altered homeostasis due to inflammation and decreased iron utilization are main factors involved in anemia in liver disease.
- Trial name
- NCT04335058
- Testing
- Lactoferrin + Iron Supplement, Iron Supplement
- Where
- India
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
HIV Infections, Hepatitis C
Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Antiretroviral (ARV) Naive Patients Starting Treatment With Anti-HCV Therapy
The purpose of this study is to evaluate if the combination of Lpv/r monotherapy and anti-HCV drugs does not match with additional toxicity induced by the association of HAART and Peg-IFN + ritonavir in patients naive for HIV and…
- Trial name
- NCT00437476
- Testing
- LPV/r, Nucleoside Reverse Transcriptase Inhibitors, PEG-IFNa 2a
- Where
- Italy
- Volunteers
- 60 people
- Sponsor
- IRCCS San Raffaele
Liver Cirrhosis
A Study to Test Whether BI 3802876 is Tolerated in People With Compensated Liver Cirrhosis Due to Metabolic Dysfunction- Associated Steatohepatitis (MASH)
This study is open to adults with a type of confirmed liver condition called compensated cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH).
- Trial name
- NCT07325526
- Testing
- BI 3802876
- Where
- 27 sites in United States, Canada
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
Liver Cirrhosis, Hepatitis B
Clinical Effects and Cost-effectiveness Analysis of Early Anti-viral Therapy on HBV-related Compensated Liver Cirrhosis
Though newly reported HBV infection and HBsAg prevalence in China have greatly decreased, patients who had been chronically infected with HBV, especially those with liver cirrhosis cause great burden on public health care.
- Trial name
- NCT01720238
- Testing
- Entecavir, Lamivudine plus Adefovir Dipivoxil
- Where
- 8 sites in China
- Volunteers
- 621 people
- Sponsor
- Beijing Friendship Hospital
Coginitive Dysfunction, Compensated Liver Cirrhosis
Examining the Effects of Different Resistive Exercise Programs in Individuals With Compensated Liver Cirrhosis
Reasons such as sleep disorders, depression, decreased independence in daily living activities and decreased quality of life, which are seen in the majority of liver cirrhosis patients, can cause cognitive dysfunction, especially…
- Conditions
- Coginitive Dysfunction, Compensated Liver Cirrhosis, Physical Dysfunction, Sarcopenia
- Trial name
- NCT06749340
- Testing
- Assigned Interventions, Face-to-face Exercise, Home-based Exercise
- Where
- Turkey (Türkiye)
- Volunteers
- 20 people
- Sponsor
- Bahçeşehir University
Cirrhosis
Terlipressin in Cirrhotic Patients With Recidivation Ascites Treated With Paracentesis and Albumin
Ascites is a common complication of cirrhosis. Sodium restriction and diuretics are the first step treatment. Refractory ascites (not responding to first step treatment) is treated with repeated large volume paracentesis followed…
- Trial name
- TERAS (NCT00986817)
- Testing
- Terlipressin
- Where
- France
- Volunteers
- 82 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.